Early Treatment With Docetaxel for Metastatic Prostate Cancer

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

The ECLIPSE trial, a pivotal, phase 3, multi-center, open-label, randomized clinical study, has met its primary end point in metastatic castration-resistant prostate cancer.

The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay additional treatments post-surgery.